Bladder cancer has a five-year survival rate of over 80% when detected early, but this rate declines significantly as the disease progresses to advanced stages. In a novel study in The Journal of ...

Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder ...

A promising molecular diagnostic tool for detecting primary bladder cancer in patients who notice blood in their urine may speed up diagnosis and reduce the need for potentially unnecessary ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine cytology), a cystoscopy to visualize the inside of the bladder, and/or a CT ...

a, Schematic illustration of the workflow of the BLOOM assay. b,c, Mechanism of organogel messenger release from the biomarker-degradable bigel film (b) and solvatochromic dye transfer to the organic ...

Tests for early prediction and diagnosis of bladder cancer were unveiled recently at the European Association of Urology annual meeting in Milan.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as ...

Acupath Laboratories, a leading provider of subspecialized anatomic pathology services, today announced a strategic partnership with Valar Labs to offer Vesta Bladder, Valar Labs’ AI-powered ...